Rui'an Xing
瑞鞍星
elsewhere's corpus does not genuinely cover Rui'an Xing as a subject. The only direct mention places it in a portfolio list of Dalton Venture-backed companies as of spring 2024, alongside biotech and medtech peers like 博创生物, 冰晶智能, and 瀚辰光翼 . No chunk in the bundle describes what the company does, when it was founded, who runs it, or what it has raised. The entity cards for associated persons—Mulyono Xu, Kyle Jiang, Zai Xing, Tim Wang—appear to be noise from retrieval matching rather than verified leadership –, and none are tied to Rui'an Xing by any relation in the supplied material.
AI-generated — may contain errors, please verify.
Coverage
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
Spring in Full Bloom, Brilliance Across All Things | Dalton Venture's 2024 CEO Summit Successfully Held
The annual Two Sessions have always been a critical barometer for China's economic trajectory and policy direction. This March, when the government elevated "new quality productive forces" to the top of its work agenda, it sparked intense interest and vigorous debate across industries about this buzzword. As one of the most dynamic drivers of technological innovation and industrial transformation—and a strategic emerging industry that lies at the heart of future industrial planning—how should the medical sector translate new quality productive forces into practice? And where will it steer the development and transformation of the life sciences industry?
New Order, New Positioning, New Engine | Dalton Venture 2023 Annual Partners Meeting Successfully Held
One gathering closes, another horizon opens. Keep exploring the boundless frontier of innovation!
